Search

Your search keyword '"Singer C.F."' showing total 254 results

Search Constraints

Start Over You searched for: Author "Singer C.F." Remove constraint Author: "Singer C.F."
254 results on '"Singer C.F."'

Search Results

1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

4. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

7. Clinical, splicing and functional analysis to classify BRCA2 exon 3 variants

8. 123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)

9. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.

10. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

11. P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

16. 165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial

17. 73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial

18. 195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis

21. 283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry

22. 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial

24. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

25. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

26. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

27. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

28. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

29. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

30. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

32. 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)

33. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

34. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

35. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

36. Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium

37. Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium.

38. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

39. Erratum: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast Cancer Res (2020) 22 (8) DOI: 10.1186/s13058-020-1247-4).

40. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

41. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

42. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

43. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.

44. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

45. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

46. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

48. Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

Catalog

Books, media, physical & digital resources